Although there are some debates [26, 27], lipophilic statins (atorvastatin, simvastatin, pitavastatin, and fluvastatin), especially at high intensity, may lead to unfavorable metabolic effects, including reduction of insulin secretion and exacerbation of insulin resistance [28, 29] and hydrophilic statins (rosuvastatin and pravastatin) could reduce the risk of cardiovascular disease compared with lipophilic statins [30, 31]. This evidence concerns the gene INS and cardiovascular disorder.